23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Cullinan Therapeutics, Inc. › 2025-2026

Cullinan Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Cullinan Therapeutics, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 183Asset managers, any item
  • 905Fund votes
  • June 16, 2026Meeting date

Results at a glance

Meeting of June 16, 2026: 4 items on Cullinan Therapeutics, Inc.’s Form 8-K, filed June 16, 2026: 2 approved · 2 passed (calculated).

Dissent

Significant dissent: 2 directors (25.5%, 24.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Cullinan Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Cullinan Therapeutics, Inc.

These tallies are Cullinan Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Cullinan Therapeutics, Inc. — official shareholder meeting results, meeting held June 16, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Nadim Ahmed 37,519,241---- 12,116,7594,126,430 76%Passed (calculated)—
Elect Director: Stephen Webster 36,963,086---- 12,672,9144,126,430 74%Passed (calculated)—
2. Ratification of Appointment of Independent Registered Accounting Firm 53,722,47736,8153,138 --0 99.9%Approved—
3. Advisory Vote on Executive Compensation 48,536,7341,092,2097,057 --4,126,430 98%Approved—

Source: Cullinan Therapeutics, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.

How asset managers voted at the Cullinan Therapeutics, Inc. 2025-2026 meeting

183 asset managers disclosed a vote on at least one Cullinan Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Nadim Ahmed

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD
FOR: 37,519,241WITHHELD: 12,116,759
Details: description as filed, official tally, votes by 50 asset managers

Description as filed by funds: Election of the following individuals nominated to serve as Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2029: Nadim Ahmed

Cullinan Therapeutics, Inc.’s own tally for this item (“Elect Director: Nadim Ahmed”): 37,519,241 for, 12,116,759 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 10,971,822 for, 803,936 withheld, 26,165 abstained.

FOR
FOR: 10,971,822ABSTAIN: 26,165WITHHOLD: 803,936
Largest asset managers voting on “Election of the following individuals nominated to serve as Class III directors, for a three-year term ending ” at Cullinan Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,020,8800 274,487For
T. Rowe Price1,612,5290 00For
BlackRock1,600,6380 00For
State Street1,411,6810 03,403For
Fidelity1,270,3150 00For
TIAA741,8260 00For
Charles Schwab433,2750 00For
Dimensional00 0374,677Withhold
American Century00 0146,920Withhold
JPMorgan135,4390 00For
Equitable95,5650 028,210Mixed
Invesco108,7110 00For
Bridge Builder Trust75,5060 00For
Brighthouse56,6170 018,364Mixed
Northern Trust73,1730 00For
Lincoln Financial48,6180 023,561Mixed
Tema ETF Trust63,6360 00For
AIG/SunAmerica00 045,980Withhold
ProShares00 040,398Withhold
Prudential/PGIM27,8000 05,658Mixed
John Hancock15,2000 13,8650Mixed
Advisor Managed Portfolios28,2550 00For
MFS00 026,506Withhold
Goldman Sachs23,4800 00For
Global X23,2110 00For

Showing the 25 largest of 50 asset managers. All 50 are in the interactive database (link above).

Elect Director: Stephen Webster

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 36,963,086WITHHELD: 12,672,914
Details: description as filed, official tally, votes by 50 asset managers

Description as filed by funds: Election of the following individuals nominated to serve as Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2029: Stephen Webster

Cullinan Therapeutics, Inc.’s own tally for this item (“Elect Director: Stephen Webster”): 36,963,086 for, 12,672,914 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 10,844,651 for, 879,312 withheld, 77,960 abstained.

FOR
FOR: 10,844,651ABSTAIN: 77,960WITHHOLD: 879,312
Largest asset managers voting on “Election of the following individuals nominated to serve as Class III directors, for a three-year term ending ” at Cullinan Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,018,6770 276,690For
T. Rowe Price1,612,5290 00For
BlackRock1,600,6380 00For
State Street1,411,6810 03,403For
Fidelity1,270,3150 00For
TIAA741,8260 00For
Charles Schwab433,2750 00For
Dimensional00 0374,677Withhold
American Century00 0146,920Withhold
JPMorgan135,4390 00For
Equitable95,5650 028,210Mixed
Invesco108,7110 00For
Bridge Builder Trust23,7110 51,7950Mixed
Brighthouse56,6170 018,364Mixed
Northern Trust00 073,173Withhold
Lincoln Financial48,6180 023,561Mixed
Tema ETF Trust63,6360 00For
AIG/SunAmerica00 045,980Withhold
ProShares00 040,398Withhold
Prudential/PGIM27,8000 05,658Mixed
John Hancock15,2000 13,8650Mixed
Advisor Managed Portfolios28,2550 00For
MFS00 026,506Withhold
Goldman Sachs23,4800 00For
Global X23,2110 00For

Showing the 25 largest of 50 asset managers. All 50 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 48,536,734AGAINST: 1,092,209

Prior year: 95.9% for (June 12, 2025 meeting) ▲ 1.9 pts

Details: description as filed, official tally, votes by 183 asset managers

Description as filed by funds: PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.

Cullinan Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 48,536,734 for, 1,092,209 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three — Advisory Vote on Executive Compensation The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 50 asset managers voting on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.” at Cullinan Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,025,3931 00For
T. Rowe Price1,612,5290 00For
BlackRock1,600,6380 00For
State Street1,414,568516 00For
Fidelity1,270,3150 00For
TIAA741,8260 00For
Charles Schwab433,2750 00For
Dimensional374,6770 00For
American Century0146,920 00Against
JPMorgan135,4390 00For
Equitable123,7750 00For
Invesco0108,711 00Against
Bridge Builder Trust23,71151,795 00Mixed
Brighthouse74,9810 00For
Northern Trust73,1730 00For
Lincoln Financial72,1790 00For
Tema ETF Trust63,6360 00For
AIG/SunAmerica45,9800 00For
ProShares40,3980 00For
Prudential/PGIM33,4580 00For
John Hancock29,0650 00For
Advisor Managed Portfolios28,2550 00For
MFS26,5060 00For
Goldman Sachs23,4800 00For
Global X23,2110 00For

Fund voting reports, all 50 managers: 11,493,980 for, 307,943 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 147 asset managers voting on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.” at Cullinan Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Lynx1 Capital Management LP8,963,5000 00For
MPM BioImpact LLC7,648,2680 00For
BVF INC/IL4,362,0440 00For
State Street2,460,7162,617 00For
T. Rowe Price2,271,3370 00For
Blue Owl Capital Holdings LP1,814,7640 00For
Kynam Capital Management, LP00 01,808,334Withhold
RTW INVESTMENTS, LP1,705,9600 00For
BlackRock1,601,02026,332 00For
Venrock Adviser, LLC1,379,9650 00For
GEODE CAPITAL MANAGEMENT, LLC1,354,7230 00For
Siren, L.L.C.1,193,4100 00For
Nuveen755,7750 00For
GREAT POINT PARTNERS LLC600,0000 00For
BOONE CAPITAL MANAGEMENT LLC491,4000 00For
Charles Schwab433,5690 00For
Vanguard406,1810 00For
DEERFIELD MANAGEMENT COMPANY, L.P.386,1690 00For
Affinity Asset Advisors, LLC361,6840 00For
Invesco0290,890 00Against
Point72278,3190 00For
Northern Trust243,9662,618 00For
Two Sigma243,4340 00For
ORBIMED ADVISORS LLC243,0060 00For
AQR206,5970 00For

Institutional-manager reports, all 147 managers: 41,282,263 for, 737,564 against, 1,808,334 withheld, 193 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 53,722,477AGAINST: 36,815

Prior year: 99.7% for (June 12, 2025 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 50 asset managers

Description as filed by funds: Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2026.

Cullinan Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 53,722,477 for, 36,815 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026 by the following votes:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 11,801,867 for, 56 against.

FOR
FOR: 11,801,867AGAINST: 56
Largest asset managers voting on “Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public account” at Cullinan Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,025,3940 00For
T. Rowe Price1,612,5290 00For
BlackRock1,600,6380 00For
State Street1,415,02856 00For
Fidelity1,270,3150 00For
TIAA741,8260 00For
Charles Schwab433,2750 00For
Dimensional374,6770 00For
American Century146,9200 00For
JPMorgan135,4390 00For
Equitable123,7750 00For
Invesco108,7110 00For
Bridge Builder Trust75,5060 00For
Brighthouse74,9810 00For
Northern Trust73,1730 00For
Lincoln Financial72,1790 00For
Tema ETF Trust63,6360 00For
AIG/SunAmerica45,9800 00For
ProShares40,3980 00For
Prudential/PGIM33,4580 00For
John Hancock29,0650 00For
Advisor Managed Portfolios28,2550 00For
MFS26,5060 00For
Goldman Sachs23,4800 00For
Global X23,2110 00For

Showing the 25 largest of 50 asset managers. All 50 are in the interactive database (link above).

Largest Cullinan Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,451,380 shares outstanding at the time of that meeting.

Fund voting reports: top Cullinan Therapeutics, Inc. shareholders by shares voted on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 4.92%
2T. Rowe Price 2.62%
3BlackRock 2.60%
4State Street 2.30%
5Fidelity 2.07%
6TIAA 1.21%
7Charles Schwab 0.71%
8Dimensional 0.61%
9American Century 0.24%
10JPMorgan 0.22%
Institutional-manager reports: top Cullinan Therapeutics, Inc. shareholders by shares voted on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.”, 2025-2026
#Asset manager % of shares outstanding
1Lynx1 Capital Management LP 14.59%
2MPM BioImpact LLC 12.45%
3BVF INC/IL 7.10%
4State Street 4.01%
5T. Rowe Price 3.70%
6Blue Owl Capital Holdings LP 2.95%
7Kynam Capital Management, LP 2.94%
8RTW INVESTMENTS, LP 2.78%
9BlackRock 2.65%
10Venrock Adviser, LLC 2.25%

Reported Cullinan Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Cullinan Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BVF PARTNERS L P/IL6,491,123 10.56%Schedule 13G, filed August 14, 2026
BlackRock4,449,966 7.24%Form 13F, quarter ended March 31, 2026
Vanguard Group3,298,504 5.37%Form 13F, quarter ended March 31, 2026
State Street2,544,115 4.14%Form 13F, quarter ended March 31, 2026
T. Rowe Price2,029,719 3.30%Form 13F, quarter ended March 31, 2026
Geode Capital1,368,268 2.23%Form 13F, quarter ended March 31, 2026
Dimensional Fund Advisors906,028 1.47%Form 13F, quarter ended March 31, 2026
Point72905,376 1.47%Form 13F, quarter ended March 31, 2026
Morgan Stanley766,934 1.25%Form 13F, quarter ended March 31, 2026
Two Sigma522,047 0.85%Form 13F, quarter ended March 31, 2026

Percentages above are of 61,451,380 shares outstanding, as reported by Cullinan Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Cullinan Therapeutics, Inc.'s shareholder meeting held June 16, 2026, in the 2025-2026 proxy season, 183 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 905 separate fund positions. On the most widely held item on that ballot — PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION. — Cullinan Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Cullinan Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cullinan Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Cullinan Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Cullinan Therapeutics (CGEM) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/cullinan-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.